Formation of the Scandinavian Obesity Surgery Registry, SOReg.

Obesity surgery is expanding, the quality of care is ever more important, and learning curve assessment should be established. A large registry cohort can show long-term effects on obesity and its comorbidities, complications, and long-term side effects of surgery, as well as changes in health-related quality of life (QoL). Sweden is ideally suited to the task of data collection and audit, with universal use of personal identification numbers, nation-wide registries permitting cross-matching to analyze causes of death, in-hospital care, and health-related absenteeism

Is the Roux Limb a Determinant for Meal Size After Gastric Bypass Surgery?

The Roux-Y gastric bypass (RYGBP) is an effective weight-reducing procedure but the involved mechanisms of action are obscure. The Roux limb is the intestinal segment that following surgery is the primary recipient for food intake. The aims of the study were to explore the mechanosensory and biomechanical properties of the Roux limb and to make correlations with preferred meal size. Ten patients participated and were examined preoperatively, 6 weeks and 1 year after RYGBP. Each subject ingested unrestricted amounts of a standardized meal and the weight of the meal was recorded. On another study day, the Roux limb was subjected to gradual distension by the use of an intraluminal balloon. Luminal volume–pressure relationships and thresholds for induction of sensations were monitored. At 6 weeks and 1 year post surgery, the subjects had reduced their meal sizes by 62% and 41% (medians), respectively, compared to preoperative values. The thresholds for eliciting distension-induced sensations were strongly and negatively correlated to the preferred meal size. Intraluminal pressure during Roux limb distension, both at low and high balloon volumes, correlated negatively to the size of the meal that the patients had chosen to eat. The results suggest that the Roux limb is an important determinant for regulating food intake after Roux-Y bypass bariatric surgery

Decreased energy density and changes in food selection following Roux-en-Y gastric bypass

Background/Objectives:The main objective was to test the hypothesis that dietary energy density (DED) decreases after Roux-en-Y gastric bypass (gastric bypass).Subjects/Methods:A total of 43 patients (31 women and 12 men) aged 43 (s.d. 10) years, with body mass index (BMI) 44.3 kg/m 2 (4.9), were assessed preoperatively at 6 weeks and 1 and 2 years after gastric bypass. Self-reported energy intake (EI), food weight (FW) and food choice were assessed using a dietary questionnaire. DED was calculated by dividing EI by FW (kcal/g). Number of dropouts was 4 of 203 visits.Results:Percent weight loss (%WL) was 13.5% at 6 weeks, 30.7% at 1 year and 31.8% at 2 years post surgery (P\u3c0.001 for all). EI decreased from 2990 to 1774, 2131 and 2425 kcal after 6 weeks and 1 and 2 years postoperatively, respectively (P\u3c0.001 at all time points). FW changed from 2844 to 1870 g/day at 6 weeks (P\u3c0.001) and 2416 g/day after 1 year (P\u3c0.05), but was not significantly different from baseline 2 years postoperatively (2602 g/day, P=0.105). DED decreased from 1.07 to 0.78 kcal/g at 6 weeks (P\u3c0.001) and 0.90 kcal/g (P\u3c0.001) and 0.96 kcal/g (P=0.001) after 1 and 2 years, respectively. All statistical comparisons were made from baseline. There was no correlation between changes in DED and %WL, neither after 1 year (r=-0.215; P=0.183) nor after 2 years (r=-0.046; P=0.775) post surgery.Conclusions:Besides substantial reduction in EI and large variation in FW, patients reported decreased DED over 2 years following gastric bypass. Despite lack of association between the reduction in DED and percentage weight loss, changes in food choice were overall nutritionally beneficial. © 2013 Macmillan Publishers Limited All rights reserved

Studies on dietary intake, eating behavior and meal-related symptoms

Background and aims: Roux-en-Y gastric bypass (RYGB) is now a common treatment for obesity with well-documented effects on long-term weight reduction, health-related quality of life, obesity-related morbidity and mortality. There is a need for a better understanding of changes in dietary intake and meal-related symptoms after RYGB. The aim of this thesis was to study these phenomena and to improve current treatment protocols. Methods: Forty-three adults (31 women, 12 men; mean age 42.6 years, mean BMI 44.5 kg/m²) were followed in a longitudinal cohort study and examined preoperatively and at six weeks, one and two years after surgery (Paper I and II). They completed the Three-Factor Eating Questionnaire (TFEQ-R21) on attitudes to food, and questionnaires on dietary intake and meal pattern; in addition, a test meal ad libitum was administered and portion size and eating rate were assessed. A Dumping Symptom Rating Scale (DSRS) was developed and evaluated for its reliability and construct validity over two years on 124 respondents of whom 43 adults from Paper I and II and in addition 81 adolescents (Paper III). Thirty-one non-obese subjects served as reference group (Paper II and III). Another eight RYGB patients with hypoglycemia -like symptoms and eight patients with no hypoglycemia -like symptoms ingested a liquid carbohydrate meal. Insulin, plasma glucose, glucagon-like peptide 1 (GLP-1) and glucagon were measured intermittently up to 180 minutes after the meal. Results: The dietary questionnaire showed decreased energy intake, Food weight fell initially but was not lower two years after surgery resulting in a significantly decreased dietary energy density at two years after surgery. The meal test showed decreased portion size despite meal duration remaining constant, resulting in a reduced eating rate. Number of meals increased, with more meals in the mornings. TFEQ-R21 revealed decreased emotional and uncontrolled eating, whereas there was a transient increase in cognitive restraint six weeks after surgery. Most subjects reported mild or no dumping symptoms, although 6–12% had persistent problems – in particular, postprandial fatigue, need to lie down, nausea, and feeling faint – two years after surgery. The result of the validation process of DSRS was satisfactory overall. The patients with a history of hypoglycemia-like symptoms after RYGB demonstrated neither lower plasma glucose nor greater insulin response compared to asymptomatic patients in response to a liquid carbohydrate meal, but they perceived more symptoms. Conclusion: After RYGB, patients displayed major changes in eating behavior and meal pattern, suggesting that RYGB drives the individual to an eating behavior that promotes weight loss. Despite lack of association between the reduction in dietary energy density and percentage weight loss, changes in food choice were overall nutritionally beneficial. Dumping symptoms were rarely evident, but some patients reported persistent problems up to two years after surgery. DSRS is a reliable clinical screening instrument to identify patients with pronounced dumping symptoms. The mechanisms of action behind the origin of hypoglycemia-like symptoms remain obscure and need further exploration

International consensus on the diagnosis and management of dumping syndrome

Dumping syndrome is a common but underdiagnosed complication of gastric and oesophageal surgery. We initiated a Delphi consensus process with international multidisciplinary experts. We defined the scope, proposed statements and searched electronic databases to survey the literature. Eighteen experts participated in the literature summary and voting process evaluating 62 statements. We evaluated the quality of evidence using grading of recommendations assessment, development and evaluation (GRADE) criteria. Consensus (defined as >80% agreement) was reached for 33 of 62 statements, including the definition and symptom profile of dumping syndrome and its effect on quality of life. The panel agreed on the pathophysiological relevance of rapid passage of nutrients to the small bowel, on the role of decreased gastric volume capacity and release of glucagon-like peptide 1. Symptom recognition is crucial, and the modified oral glucose tolerance test, but not gastric emptying testing, is useful for diagnosis. An increase in haematocrit >3% or in pulse rate >10 bpm 30 min after the start of the glucose intake are diagnostic of early dumping syndrome, and a nadir hypoglycaemia level <50 mg/dl is diagnostic of late dumping syndrome. Dietary adjustment is the agreed first treatment step; acarbose is effective for late dumping syndrome symptoms and somatostatin analogues are preferred for patients who do not respond to diet adjustments and acarbose. © 2020, The Author(s)

International consensus on the diagnosis and management of dumping syndrome

Dumping syndrome is a common but underdiagnosed complication of gastric and oesophageal surgery. We initiated a Delphi consensus process with international multidisciplinary experts. We defined the scope, proposed statements and searched electronic databases to survey the literature. Eighteen experts participated in the literature summary and voting process evaluating 62 statements. We evaluated the quality of evidence using grading of recommendations assessment, development and evaluation (GRADE) criteria. Consensus (defined as \textgreater80% agreement) was reached for 33 of 62 statements, including the definition and symptom profile of dumping syndrome and its effect on quality of life. The panel agreed on the pathophysiological relevance of rapid passage of nutrients to the small bowel, on the role of decreased gastric volume capacity and release of glucagon-like peptide 1. Symptom recognition is crucial, and the modified oral glucose tolerance test, but not gastric emptying testing, is useful for diagnosis. An increase in haematocrit \textgreater3% or in pulse rate \textgreater10 bpm 30 min after the start of the glucose intake are diagnostic of early dumping syndrome, and a nadir hypoglycaemia level \textless50 mg/dl is diagnostic of late dumping syndrome. Dietary adjustment is the agreed first treatment step; acarbose is effective for late dumping syndrome symptoms and somatostatin analogues are preferred for patients who do not respond to diet adjustments and acarbose